Skip to Main Content

Michael Pourdehnad

MD

Hematologist-oncologist
Cancer researcher and kids' soccer coach

Dr. Michael Pourdehnad is a hematologist-oncologist who specializes in cancers that originate in blood-forming tissues or immune system cells. He also has expertise in noncancerous blood disorders.

Pourdehnad is a physician-scientist, a medical doctor who devotes much of his time to research. In addition to treating patients, he is dedicated to developing novel therapies for cancer patients with especially challenging cases. In this capacity, he works with the biotechnology company Celgene to translate research discoveries into new treatments for blood cancers.

After earning his medical degree from the Chicago Medical School at Rosalind Franklin University School of Medicine and Science, Pourdehnad completed a residency in internal medicine at Icahn School of Medicine at Mount Sinai, where he served as chief resident. He then completed a fellowship in adult hematologic malignancies and blood and marrow transplantation at UCSF.

  • Education

    Chicago Medical School at Rosalind Franklin University School of Medicine and Science, 2005

  • Residencies

    Icahn School of Medicine at Mount Sinai, Internal Medicine, 2008

  • Fellowships

    UCSF, Adult Hematologic Malignancies and Blood and Marrow Transplantation, 2012

Connection with my patients and their challenges inspires and drives my efforts to develop innovative new therapies.

Where I see patients (1)

    My reviews

    4.8

    Overall Experience
    34 Ratings
    About our process
    Apr 18, 2023
    Dr. Pourdehnad looks into my overall care since he knew that I didn't have a primary care physician for a period
    Mar 21, 2023
    All good. The best.
    Dec 01, 2022
    Stated he was ordering labs which have not been recieved to any of the santa rosa sutter labs. I sent a message however haven't heard back
    Aug 09, 2022
    Dr. Pourdehnad was the specialist I was looking for and his working knowledge gives me confidence going forward.
    Aug 09, 2022
    Very good

    Share